About journey medical corp - DERM
Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its brands include QBREXZA, Accutane, Targadox, AMZEEQ, Ximino, ZILXI, Exelderm, and Luxamend. The company was founded by Claude Maraoui in October 2014 and is headquartered in Scottsdale, AZ.
DERM At a Glance
Journey Medical Corp.
9237 E Via de Ventura Boulevard
Scottsdale, Arizona 85258
| Phone | 1-480-434-6670 | Revenue | 61.86M | |
| Industry | Pharmaceuticals: Major | Net Income | -11,431,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 10.197% | |
| Fiscal Year-end | 12 / 2026 | Employees | 58 | |
| View SEC Filings |
DERM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.053 |
| Price to Book Ratio | 6.571 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -49.709 |
| Enterprise Value to Sales | 3.075 |
| Total Debt to Enterprise Value | 0.134 |
DERM Efficiency
| Revenue/Employee | 1,066,517.241 |
| Income Per Employee | -197,086.207 |
| Receivables Turnover | 2.077 |
| Total Asset Turnover | 0.708 |
DERM Liquidity
| Current Ratio | 1.786 |
| Quick Ratio | 1.529 |
| Cash Ratio | 0.643 |
DERM Profitability
| Gross Margin | 59.291 |
| Operating Margin | -13.211 |
| Pretax Margin | -18.382 |
| Net Margin | -18.479 |
| Return on Assets | -13.077 |
| Return on Equity | -44.032 |
| Return on Total Capital | -19.968 |
| Return on Invested Capital | -22.367 |
DERM Capital Structure
| Total Debt to Total Equity | 79.731 |
| Total Debt to Total Capital | 44.361 |
| Total Debt to Total Assets | 26.849 |
| Long-Term Debt to Equity | 79.414 |
| Long-Term Debt to Total Capital | 44.185 |